Analyst Tracker/Swayampakula Ramakanth

Swayampakula Ramakanth

Q: How accurate are Swayampakula Ramakanth's stock ratings?

About 46% of Swayampakula's ratings were profitable over a one-year hold, with an average return of +3.3% per rating, measured by 13Foresight from historical prices.

Q: How is Swayampakula ranked?

Swayampakula Ramakanth is ranked #2262 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★☆☆☆

#2262

on 13Foresight · ranked by our own returns

46%

Success Rate

+3.3%

Average Return

85 of 186 calls profitable · +22.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 46% of Swayampakula Ramakanth's ratings turned a profit when each position was held for 1 year — averaging +3.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

279 Buy 12 Hold 0 Sell

Swayampakula's Stock Coverage 91 ratings · 2026-10-02

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CGEN Compugen	Oct 01, 2026	BUY	Strong Buy +130.7% avg upside 8 analysts	$4.00 66.94% Upside	·	·
PYXS Pyxis Oncology	Oct 01, 2026	BUY	Strong Buy +271.9% avg upside 15 analysts	$8.00 260.28% Upside	·	·
ABSI AbSci	Oct 01, 2026	BUY	Strong Buy +15.5% avg upside 19 analysts	$16.00 47.65% Upside	·	·
JANX Janux Therapeutics Inc	Oct 01, 2026	BUY	Strong Buy +166.9% avg upside 22 analysts	$45.00 163.40% Upside	·	·
EVAX Evaxion Biotech	Oct 01, 2026	BUY	Strong Buy +294.5% avg upside 6 analysts	$16.00 406.23% Upside	·	·
TLSI TriSalus Life Sciences	Oct 01, 2026	BUY	Strong Buy +139.6% avg upside 9 analysts	$12.00 188.37% Upside	·	·
INAB IN8bio	Oct 01, 2026	BUY	Buy +5631.9% avg upside 5 analysts	$6.00 315.30% Upside	·	·
IPHA Innate Pharma	Oct 01, 2026	BUY	Strong Buy +339.8% avg upside 10 analysts	$7.00 334.78% Upside	·	·
ALXO ALX Oncology Holdings	Oct 01, 2026	BUY	Strong Buy +1284.7% avg upside 11 analysts	$4.00 196.27% Upside	+0.0%	·
ETON Eton Pharmaceuticals	Oct 01, 2026	BUY	Strong Buy -27.9% avg upside 9 analysts	$70.00 31.88% Upside	·	·
DNTH Dianthus Therapeutics	Oct 01, 2026	BUY	Strong Buy +13.9% avg upside 31 analysts	$158.00 74.54% Upside	·	·
CELC Celcuity	Oct 01, 2026	BUY	Strong Buy +65.5% avg upside 17 analysts	$155.00 101.86% Upside	+0.0%	·
FR:NANO Nanobiotix	Oct 01, 2026	BUY	Strong Buy +136.2% avg upside 1 analyst	$60.00 136.18% Upside	·	·
OCGN Ocugen	Oct 01, 2026	BUY	Strong Buy +805.0% avg upside 17 analysts	$10.00 857.02% Upside	·	·
MDWD Mediwound	Oct 01, 2026	BUY	Strong Buy +60.3% avg upside 13 analysts	$36.00 161.94% Upside	·	·
PGEN Precigen	Oct 01, 2026	BUY	Buy +177.8% avg upside 12 analysts	$18.00 115.91% Upside	·	·
FOCL FocalTherics	Oct 01, 2026	BUY	Buy +96.3% avg upside 8 analysts	$10.00 128.78% Upside	·	·
CORT Corcept Therapeutics	Oct 01, 2026	BUY	Buy -41.9% avg upside 16 analysts	$165.00 43.74% Upside	·	·
UNCY Unicycive Therapeutics	Sep 30, 2026	BUY	Strong Buy +1055.8% avg upside 10 analysts	$13.00 176.07% Upside	·	·
CANF Can-Fite BioPharma	Sep 29, 2026	BUY	Strong Buy +130.7% avg upside 8 analysts	$8.00 258.68% Upside	+0.9%	·
QSI Quantum-Si	Sep 29, 2026	BUY	Buy +64.9% avg upside 3 analysts	$4.00 187.87% Upside	·	·
MIRM Mirum Pharmaceuticals	Sep 29, 2026	BUY	Strong Buy +40.8% avg upside 23 analysts	$195.00 128.31% Upside	-2.4%	·
HYFT MindWalk Holdings	Sep 23, 2026	BUY	Strong Buy +224.0% avg upside 3 analysts	$5.00 267.68% Upside	-0.7%	·
ACTU Actuate Therapeutics, Inc.	Sep 21, 2026	BUY	Strong Buy +1207.6% avg upside 5 analysts	$15.00 1602.13% Upside	-14.0%	·
HUMA Humacyte	Sep 21, 2026	BUY	Strong Buy +1213.0% avg upside 11 analysts	$4.00 671.37% Upside	-5.6%	·
DCTH Delcath Systems	Sep 21, 2026	BUY	Strong Buy +42.2% avg upside 11 analysts	$32.00 105.30% Upside	-3.2%	·
AEMD Aethlon Medical	Sep 18, 2026	HOLD	Buy +250.6% avg upside 3 analysts	$1.50 77.42% Downside	-0.5%	·
EVO Evotec AG	Aug 31, 2026	BUY	Buy +401.4% avg upside 9 analysts	$4.00 142.52% Upside	-17.0%	·
SOPH SOPHiA GENETICS	Aug 31, 2026	BUY	Strong Buy +30.2% avg upside 8 analysts	$14.00 74.53% Upside	+1.1%	·
BSEM BioStem Technologies	Aug 24, 2026	BUY	Strong Buy +128.0% avg upside 1 analyst	$7.00 128.04% Upside	+5.6%	·
CTXR Citius Pharmaceuticals	Aug 20, 2026	BUY	Buy +819.7% avg upside 3 analysts	$4.00 628.60% Upside	-3.5%	·
INTS Intensity Therapeutics, Inc.	Aug 20, 2026	BUY	Strong Buy +1060.7% avg upside 6 analysts	$7.00 102.96% Upside	-30.9%	·
LFWD Lifeward	Aug 20, 2026	BUY	Buy +17.4% avg upside 8 analysts	$10.00 63.94% Upside	-4.6%	·
RNXT RenovoRx	Aug 14, 2026	BUY	Strong Buy +319.9% avg upside 5 analysts	$3.00 91.67% Upside	+18.6%	·
VOR Vor Biopharma	Aug 12, 2026	BUY	Strong Buy +143.0% avg upside 17 analysts	$31.00 65.17% Upside	-17.8%	·
ECOR Electrocore	Aug 10, 2026	BUY	Strong Buy +445.5% avg upside 11 analysts	$18.00 67.65% Upside	+24.1%	·
VCEL Vericel	Jul 31, 2026	BUY	Strong Buy +16.4% avg upside 16 analysts	$72.00 78.83% Upside	-13.6%	·
CNXU Conexeu Sciences, Inc.	Jun 22, 2026	BUY	Strong Buy +471.4% avg upside 1 analyst	$20.00 471.43% Upside	-70.7%	·
CHRN ChronoScale	Dec 31, 2025	HOLD	Strong Buy +6.0% avg upside 5 analysts	—	+128.4%	·
DYAI Dyadic International	Nov 18, 2025	HOLD	Buy +812.9% avg upside 3 analysts	—	-53.3%	·
PSNL Personalis	Nov 18, 2025	HOLD	Strong Buy -7.0% avg upside 11 analysts	—	+113.8%	·
CYPH Cypherpunk Technologies	Nov 18, 2025	HOLD	Buy +194.0% avg upside 9 analysts	—	+38.7%	·
XFOR X4 Pharmaceuticals	Nov 10, 2025	BUY	Strong Buy +737.4% avg upside 16 analysts	$5.00 70.13% Upside	-17.1%	·
BCYC Bicycle Therapeutics	Oct 31, 2025	BUY	Strong Buy +572.1% avg upside 21 analysts	$33.00 800.46% Upside	-54.3%	·
CLGN Collplant Holdings	Aug 21, 2025	BUY	Strong Buy +354.1% avg upside 3 analysts	$11.00 207.91% Upside	·	·
MDAI Spectral AI	Aug 14, 2025	BUY	Strong Buy +164.4% avg upside 4 analysts	$3.50 110.83% Upside	-20.0%	·
TSE:MDNA Medicenna Therapeutics Corp	Aug 04, 2025	BUY	Strong Buy +1169.9% avg upside 9 analysts	$3.56 836.89% Upside	-60.0%	·
AFMDQ Affimed	May 28, 2025	HOLD	Buy +14226263.7% avg upside 16 analysts	—	·	·
AGPU Axe Compute Inc	Nov 15, 2024	HOLD	Buy -75.2% avg upside 2 analysts	—	-37.1%	·
MDXG MiMedx Group	May 01, 2024	BUY	Strong Buy +131.3% avg upside 17 analysts	$11.00 136.02% Upside	-13.5%	·
TCRT Alaunos Therapeutics	Apr 02, 2024	HOLD	Buy +1551.8% avg upside 13 analysts	—	-84.1%	·
PLUR Pluri	Feb 15, 2024	HOLD	Strong Buy +480.8% avg upside 8 analysts	—	-25.0%	·
CDXS Codexis	Aug 07, 2023	HOLD	Strong Buy +641.9% avg upside 13 analysts	—	+21.3%	·
CELU Celularity	May 25, 2023	BUY	Buy +1015.9% avg upside 6 analysts	$25.00 1751.76% Upside	-42.8%	·
CRVO CervoMed	Mar 06, 2023	HOLD	Strong Buy +526.1% avg upside 9 analysts	—	+74.0%	·
PLSE Pulse Biosciences	Mar 06, 2023	HOLD	Strong Buy +8.3% avg upside 8 analysts	—	+234.7%	·
CLRB Cellectar Biosciences	Mar 06, 2023	HOLD	Buy +3942.1% avg upside 8 analysts	—	·	·
NTBLQ Notable Labs	Mar 06, 2023	HOLD	Buy +809999900.0% avg upside 12 analysts	—	·	·
CASIF CASI Pharmaceuticals	Aug 15, 2022	BUY	Buy +21935.9% avg upside 5 analysts	$12.00 11306.83% Upside	·	·
MESO Mesoblast	Jun 01, 2022	BUY	Strong Buy +76.9% avg upside 14 analysts	$16.00 11.00% Upside	+1.7%	·
CRVS Corvus Pharmaceuticals	May 11, 2022	BUY	Strong Buy +131.8% avg upside 14 analysts	$6.00 47.76% Downside	+84.5%	·
CARM Carisma Therapeutics	Nov 09, 2021	HOLD	Hold +484900.0% avg upside 11 analysts	—	·	·
CATX Perspective Therapeutics	Mar 26, 2021	HOLD	Strong Buy +305.6% avg upside 24 analysts	—	-66.1%	·
FR:AB AB Science SA	Mar 26, 2021	HOLD	Buy +753.2% avg upside 2 analysts	—	-36.9%	·
ZOMDF Zomedica	Jan 29, 2021	BUY	Buy +1430.6% avg upside 3 analysts	$1.20 1430.64% Upside	-68.5%	·
M Macy's	Jan 20, 2021	BUY	Buy +142.7% avg upside 35 analysts	—	+95.7%	·
INMB Inmune Bio	Nov 09, 2020	BUY	Buy +535.6% avg upside 11 analysts	$15.00 661.34% Upside	+100.0%	·
FR:OSE OSE Immunotherapeutics SA	Mar 27, 2020	BUY	Strong Buy +427.1% avg upside 4 analysts	$7.00 221.97% Upside	+286.7%	·
VSTM Verastem	Mar 16, 2020	BUY	Strong Buy +97.4% avg upside 24 analysts	$2.80 65.59% Downside	+38.6%	·
CTSO Cytosorbents	Mar 06, 2020	BUY	Strong Buy +189.7% avg upside 13 analysts	$13.00 207.21% Upside	+42.8%	·
ATEC Alphatec Holdings	Mar 06, 2020	BUY	Strong Buy +66.6% avg upside 23 analysts	$9.50 4.76% Downside	+174.6%	·
RDHL RedHill Biopharma	Mar 05, 2020	BUY	Strong Buy +4015.6% avg upside 7 analysts	$14.00 2786.61% Upside	·	·
THMO ThermoGenesis Holdings	Nov 21, 2019	BUY	Buy +7499899.9% avg upside 4 analysts	$7.50 7499899.90% Upside	·	·
TSE:CSCI COSCIENS Biopharma	Nov 11, 2019	BUY	Strong Buy +97.9% avg upside 8 analysts	$6.41 26.83% Downside	·	·
FR:IPH Innate Pharma SA	Oct 02, 2019	BUY	Strong Buy +555.8% avg upside 5 analysts	$11.00 714.82% Upside	-53.1%	·
ONTO Onto Innovation	Apr 04, 2019	BUY	Strong Buy -14.9% avg upside 17 analysts	$28.32 90.96% Downside	·	·
TARA Protara Therapeutics	Mar 18, 2019	BUY	Strong Buy +1732.4% avg upside 21 analysts	$160.00 5370.09% Upside	·	·
LLY Eli Lilly & Co	Apr 18, 2018	BUY	Strong Buy -6.9% avg upside 49 analysts	—	+47.8%	·
ADYX Adynxx	Jan 08, 2018	HOLD	Strong Buy +3387400.1% avg upside 4 analysts	$2.80 2799900.06% Upside	·	·
CLDX Celldex	May 15, 2017	BUY	Strong Buy +32.5% avg upside 28 analysts	$6.00 81.53% Downside	-77.7%	·
AGEN Agenus	May 05, 2017	HOLD	Strong Buy +40.8% avg upside 19 analysts	$5.00 44.91% Downside	·	·
KZIA Kazia Therapeutics	Feb 28, 2017	BUY	Strong Buy +176.2% avg upside 8 analysts	$20.00 109.37% Upside	·	·
IMMP Immutep	Feb 28, 2017	BUY	Buy +18.8% avg upside 7 analysts	$7.50 64.93% Upside	-37.9%	·
CAPR Capricor Therapeutics	Nov 16, 2016	BUY	Strong Buy +204.6% avg upside 12 analysts	—	-25.4%	·
IMNN Imunon	Nov 11, 2016	BUY	Strong Buy +1021.0% avg upside 11 analysts	$3.00 138.13% Upside	·	·
XTNT Xtant Medical Holdings	Aug 03, 2016	BUY	Strong Buy +1515.7% avg upside 9 analysts	—	·	·
RBSH Rebus Holdings	Mar 28, 2016	BUY	Strong Buy +199999900.0% avg upside 2 analysts	$2.00 199999900.01% Upside	·	·
XTLB XTL Biopharmaceuticals Sponsored ADR	Mar 22, 2016	BUY	Strong Buy +175.9% avg upside 1 analyst	$6.00 175.94% Upside	-59.0%	·
SRNE Sorrento Therapeutics	Dec 07, 2015	BUY	Strong Buy +3124900.0% avg upside 7 analysts	$45.00 5624899.93% Upside	·	·
SSKN Strata Skin Sciences	Aug 24, 2015	BUY	Strong Buy +599999900.0% avg upside 5 analysts	$5.00 499999899.98% Upside	·	·
ALDX Aldeyra Therapeutics	May 14, 2015	BUY	Strong Buy +1181.0% avg upside 21 analysts	$14.00 1020.01% Upside	-25.8%	·

🔒 86 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Swayampakula Ramakanth — Frequently Asked Questions

How accurate are Swayampakula Ramakanth's stock ratings?

Based on the calls 13Foresight could measure, about 46% of Swayampakula's ratings were profitable over a one-year hold, with an average return of +3.3% per rating, or +22.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Swayampakula ranked on 13Foresight?

Swayampakula Ramakanth is currently ranked #2262 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Swayampakula cover?

Swayampakula most recently has ratings on CGEN, PYXS, ABSI, JANX, EVAX, TLSI, INAB, IPHA, ALXO, ETON, DNTH, CELC and 79 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Swayampakula Ramakanth

Rating Distribution

Welcome to 13Foresight!